The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD is linked to increased mortality rates and substantial healthcare costs, primarily driven by its progression to metabolic dysfunction‐associated steatohepatitis (MASH), which can lead to severe liver complications including cirrhosis and hepatocellular carcinoma. Despite its growing burden, effective pharmacotherapy for MASLD/MASH has been lacking until the recent conditional approval of resmetirom by the FDA. Resmetirom, a liver‐targeted thyroid hormone receptor‐β selective drug, has shown promise in clinical trials for treating non‐cirrhotic MASH with moderate to advanced fibrosis. It has demonstrated efficacy in reducing hepatic fat content, improving liver histology (both MASH resolution and fibrosis improvement), and ameliorating biomarkers of liver damage without significant effects on body weight or glucose metabolism. Notably, resmetirom also exhibits favourable effects on circulating lipids, potentially reducing cardiovascular risk in MASLD/MASH patients. The safety profile of resmetirom appears acceptable, with gastrointestinal adverse events being the most common, though generally mild or moderate. However, long‐term surveillance is warranted to monitor for potential risks related to thyroid, gonadal, or bone diseases. Clinical implementation of resmetirom faces challenges in patient selection and monitoring treatment response, and will heavily rely on non‐invasive tests for liver fibrosis assessment. Nonetheless, resmetirom represents a landmark breakthrough in MASLD/MASH treatment, paving the way for future therapeutic strategies aiming to mitigate the multifaceted risks associated with this complex metabolic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“28 These data are also consistent with earlier work showing that free T3, via THR-β , directly increased expression of sterol regulatory element binding transcription factor (Srebf1), the master transcriptional regulator of DNL. 29 In sum, these data indicate that lipid excess in primary…”
MethodA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationYounossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100 · cited 1×
“58 However, as THR-α is involved in regulating fibrogenesis in hepatic stellate cells, a direct effect of modulation of the thyroid axis on hepatic fibrogenesis cannot presently ruled out.”
BackgroundSelf-citationFree Radicals: Properties, Sources, Targets, and Their Implication in Various Diseases
Phaniendra, A., Jestadi, D. B., & Periyasamy, L. (2015) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-014-0446-0 · Cited by 2,886
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084 · cited 9×
“When looking at the resmetirom target population, the MAESTRO-NASH trial, 11 as for FDA recommendations, 44 enrolled adult patients with histological diagnosis of at-risk MASH, defined as MASH with fibrosis stage F2/F3.”
BackgroundMethodInfluentialBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Self-citationKronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703 · cited 1×
“39 Based on Mendelian randomization studies, 40 it could be estimated, as shown in Table 2 , that the observed resmetirom-induced improvement in circulating lipids would reduce major adverse cardiovascular events by 16–21%, respectively.”
BackgroundKarlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Self-citationHarrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine · doi:10.1038/s41591-023-02603-1 · Cited by 435 · cited 6×
“11,37 Most adverse events were usually mild or moderate in severity.”
BackgroundInfluentialBianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385 · cited 2×
“The positive clinical trial results of resmetirom on the histological resolution of MASH and improvement of liver fibrosis confirm the prediction based on human genetics, Mendelian randomization studies and pathophysiological data that targeting hepatic fat accumulation would result in stopping and reversing the natur…”
BackgroundDongiovanni, P., Stender, S., Pietrelli, A., Mancina, R. M., Cespiati, A., Petta, S., Pelusi, S., Pingitore, P., Badiali, S., Maggioni, M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12719 · Cited by 367 · cited 2×
“…and pathophysiological data that targeting hepatic fat accumulation would result in stopping and reversing the natural history of MASLD from isolated steatosis to advanced fibrosis, cirrhosis, 7,8 and even HCC, 56 as observed for cholesterol accumulation in the arterial wall for atherosclerosis.”
BackgroundSelf-citationNon-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA · doi:10.1001/jama.2024.1447 · Cited by 250 · cited 1×
“52 The availability of resmetirom in real life opens another key question: how and when to define the response to the treatment?”
BackgroundSelf-citationKelly, M. J., Pietranico-Cole, S., Larigan, J. D., Haynes, N.-E., Reynolds, C. H., Scott, N., Vermeulen, J., Dvorozniak, M., Conde-Knape, K., Huang, K.-S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4019299 · Cited by 231
Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00017-1 · Cited by 224 · cited 1×
“46,47 Overall, these NITs have acceptable-good accuracy, but the real question is whether they can be nowadays used in routine clinical practice to select patients for treatment.”
BackgroundSelf-citationPetta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197
Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications · doi:10.1002/hep4.1657 · Cited by 197
Bruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00475 · Cited by 108
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93 · cited 1×
“26 Consistent with these mouse observations, linkage studies showed that humans bearing THR-β loss- of-function variants had greater hepatic fat content on ultrasound than relatives with wild-type alleles, 27 interrupting the expected positive relationship between BMI and hepatic fat accumulation.”
BackgroundSelective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH
Cusi, K. (2024) · New England Journal of Medicine · doi:10.1056/nejme2314365 · Cited by 78 · cited 1×
“42 Definitive answers will come from the 54-month long-term safety and efficacy results of the ongoing MAESTRO-NASH trial, as well as the routine post-marketing surveillance of adverse events once the drug is on the market.”
BackgroundIncreased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta
Chaves, C., Bruinstroop, E., Refetoff, S., Yen, P. M., & Anselmo, J. (2021) · Thyroid® · doi:10.1089/thy.2020.0651 · Cited by 55 · cited 1×
“26 Consistent with these mouse observations, linkage studies showed that humans bearing THR-β loss- of-function variants had greater hepatic fat content on ultrasound than relatives with wild-type alleles, 27 interrupting the expected positive relationship between BMI and hepatic fat accumulation.”
Background
Cited by
Global burden of metabolic diseases, 1990–2021
Zhang, H., Zhou, X.-D., Shapiro, M. D., Lip, G. Y. H., Tilg, H., Valenti, L., Somers, V. K., Byrne, C. D., Targher, G., Yang, W., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155999 · Cited by 368
Self-citationMetabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Self-citationMASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“In the phase 3 trials, MAESTRO-NAFLD-1 [294] and MAESTRO-MASH [295], resmetirom effectively reduced liver steatosis in non-cirrhotic MASH adults with significant liver fibrosis [296].”
Constructing biomimetic microenvironments for liver regeneration
(2025) · doi:10.1186/s12951-025-03729-9 · Cited by 11
Metadata
- Authors
- Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2024-04-05
- Volume
- 44
- Issue
- 7
- Pages
- 1526-1536
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W4393992983
- Cited by
- 171
- References
- 25
- FWCI
- 44.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.